For the first time, cloning technologies have been used to generate stem cells that are genetically matched to adult patients.
Fear not: No legitimate scientist is in the business of cloning humans. But cloned embryos can be used as a source for stem cells that match a patient and can produce any cell type in that person (…)
“This is a dream that we’ve had for 15 years or so in the stem cell field,” said John Gearhart, director of the Institute for Regenerative Medicine at the University of Pennsylvania. Gearhart first proposed this approach for patient-specific stem cell generation in
Image via Wikipedia
Adult stem cells and their more committed kin, progenitor cells, are prized by medical researchers for their ability to produce different types of specialised cells. The potential of using these cells to repair or replace damaged tissue holds great promise for cancer therapies and regenerative medicine. However, the question that must first be answered is what determines the ultimate fate of a stem or progenitor cell? A team of researchers led by Berkeley Lab’s Mark LaBarge and Mina Bissell appear to be well on the road to finding out.
Working with unique microenvironment microarrays (MEArrays) of their own
Two scientists at the Fred Hutchinson Cancer Research Center in Seattle have been awarded $16.7 million for stem cell research projects.
Dr. Irwin Bernstein and Beverly Torok-Storb received the federal funding from the National Heart, Lung and Blood Institute. Their award is part of a $170 million effort divided among 18 scientific teams.
Torok-Storb will work with Dr. Mortimer Poncz of Children’s Hospital of Philadelphia to develop molecular and cell-based therapies for a range of blood diseases, using an $8.2 million grant.
Bernstein will work with Edward Morrisey of the University of Pennsylvania to study how biochemical reactions inside cells affect cell
Harvard Stem Cell Institute (HSCI) scientists collaborating with researchers at the University of Pennsylvania have developed a “genome-editing” approach for permanently reducing cholesterol levels in mice through a single injection, a development that could reduce the risk of heart attacks in humans by 40 to 90 percent.
“For the first iteration of an experiment, this was pretty remarkable,” said Kiran Musunuru of HSCI, an assistant professor in Harvard’s Department of Stem Cell and Regenerative Biology (SCRB), and a cardiologist at Harvard-affiliated Brigham and Women’s Hospital. Musunuru stressed, however, that it could take a decade of concerted effort to get this